Mar 20, 2022 — 5 min read
Lunit to present two abstracts about its AI-based tissue analysis platform Lunit SCOPE
Evidence supports the effectiveness of Lunit's AI-powered tumor purity assessment method using Lunit SCOPE IO
Lunit announced today its presentation of two abstracts featuring its AI-based immunotherapy response predictor at the 2022 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, held in a hybrid, online-offline format on March 19-24.
As a leading medical AI provider, Lunit focuses on developing novel AI biomarkers for application in cancer treatment. Since 2019, the company has presented groundbreaking findings using its AI-powered tissue analysis platform, 'Lunit SCOPE.' Through digital analysis of histopathological whole slide images (WSI), the studies have validated the predictive value of Lunit SCOPE in immunotherapy.
One of the USCAP abstracts showcases Lunit's AI-powered tumor purity (AI-P) assessment method using the company's AI biomarker platform, Lunit SCOPE IO–part of the Lunit SCOPE product line. Tumor purity is the proportion of cancer cells within a tissue sample and is estimated to ensure quality-controlled prediction of treatment effectiveness and prognosis. Findings from this study indicate that AI-P provides objective tumor purity quantification, validated through the consensus purity estimation based on next-generation sequencing (NGS) and pathological examination.
While advanced genomic analysis using NGS allowed for greater precision in estimating tumor purity compared to pathologic examination, direct evaluation of tumor purity assessment in a whole slide image (WSI) still faced limitations due to technical challenges. Clinical relevance between AI-P and existing tumor purity assessment methods indicate that AI-P can be used as a successful alternative to practically and expeditiously assess the tumor purity from H&E slides.
"This is our first study that validates AI-based tumor purity estimation," said Brandon Suh, CEO of Lunit. "The results reveal AI's capability to objectively analyze whole slide images compared to existing methods. Tumor purity serves as an important quality control element in NGS analysis, and an accurate assessment of tumor purity through AI can lead to increasingly accurate and cost-effective sequencing tests."
The company's other major study assessed the practical efficacy of Lunit SCOPE PD-L1, an AI-powered PD-L1 tumor proportion score (TPS) analyzer. According to the study, assistance with Lunit SCOPE PD-L1 substantially improved pathologists' consensus and prediction of clinical response to immunotherapy in advanced non-small cell lung cancer (NSCLC). These results ultimately demonstrate the AI model's effectiveness in helping to decide the most appropriate treatment for cancer patients.
Three board-certified pathologists manually evaluated the PD-L1 TPS of 479 NSCLC data, concordantly scoring in 81.4% of the cases. Following a revision of these evaluations based on AI suggestions, this overall consistency rate increased to 90.2%. Furthermore, the revised TPS group with AI assistance predicted objective response rate, progression-free survival, and overall survival better than the baseline group without AI assistance.
"While PD-L1 expression is the current standard for clinical application, manual evaluation of PD-L1 TPS by pathologists has practical limitations of interobserver bias and intensive labor," said Chan-Young Ock, Chief Medical Officer at Lunit. "Through this study, we aimed to explore whether the AI-powered TPS analyzer could reduce the interobserver variation and increase the accuracy of analyses."
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to showcase AI-powered products at USCAP 2017
Uncertainty and Deep Learning
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Renowned Oncologist Dr. Tony Mok Joins Lunit Advisory Board
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI Proves Its Value in Assistance for Emergency Cases-- With Higher Accuracy and Timely Reporting Time of Chest Radiographs
AI Can Offer Fast and Reliable Examination to Triage COVID-19 Patients-- A Multicenter Retrospective Study Reveals
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
What do medical studies say about AI for COVID-19 management?
What do the medical journals say about AI-powered mammography?
Research Using Lunit Demo Website
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
Case of the Month | Where Is Breast Cancer?
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021
Clinical Application of Lunit AI For Chest Radiography and Mammography to Be Presented at AOCR 2021
Lunit Secures $26M Investment from Guardant Health in a Strategic Funding Round
A Multi-reader Study Finds Unnecessary CT Exams Can Be Reduced by 30% When Analyzing Chest Radiographs with AI
Fujifilm Introduces its AI-powered Product for Chest X-ray in Japan, in Collaboration with Lunit
Lunit Collaborates with Intel to Provide AI Solutions to CPU-Based Customers in Need of Effective X-ray Diagnosis
Lunit AI Applied to Clinical Trial for Drug Development for the First Time--Findings Presented at ESMO 2021
Case of the Month (Chest x-ray)
COVID Global User Testimonials
Where is Cancer?
Breast Cancer Awareness Month — Ambassador Messages
TimeSformer: Is Space-Time Attention All You Need for Video Understanding?
Evaluation curves for object detection algorithms in medical images
Lunit to Participate in RSNA 2021, Presenting its New AI Solutions for Digital Breast Tomosynthesis and Chest CT
Lunit Presents Studies at SITC 2021, Highlighting the Effectiveness of AI in Predicting Response to Immunotherapy in a Clinical Trial Setting
Lunit Gets FDA Nod for AI-based Chest X-ray Triage Solution, Developed for Sorting of Emergency Cases
Lunit's AI Software for Breast Cancer Detection, Lunit INSIGHT MMG, Wins FDA Clearance
Research Backs Clinical Efficacy of Lunit's Radiology AI Products; Abstracts to be Presented at RSNA 2021
Medical AI Provider Lunit Raises $61M in Funding Round Led By Major Global Healthcare Investors
Lunit Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Lunit Obtains MDSAP Certificate, Granted Fast-Track Regulatory Process in Major Countries
Lunit to Showcase Chest and Breast Radiology AI in Arab Health 2022
Baheya Foundation, Egypt’s Premier Destination for Breast Cancer, Adopts Lunit AI to Enhance Early Screening
Breakthrough Study Validates Artificial Intelligence as a Novel Biomarker in Predicting Immunotherapy Response - Published in Journal of Clinical Oncology
Case of the Month (Chest x-ray) - Tuberculosis Case
New Studies at AACR 2022 Highlight Lunit SCOPE’s Immune Phenotyping Capabilities
Medical AI Startup Lunit gets Preliminary Approval to go Public on KOSDAQ
Lunit AI solution for PD-L1 expression analysis receives CE mark
Lunit to Present 11 Abstracts at the 2022 ASCO Annual Meeting
Lunit AI Biomarker PD-L1 Demonstrates Clinical Efficacy as Diagnostic Aid in Cancer Treatment–Published in the European Journal of Cancer
New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment